NuCana (NCNA) EPS (Weighted Average and Diluted) (2021 - 2024)
NuCana's (NCNA) quarterly EPS (Weighted Average and Diluted) came in at $0.15 in Q2 2024, up 21.04% year-on-year from $0.13 in Q3 2023, and up 21.04% quarter-over-quarter from $0.13 in Q2 2023.
NuCana (NCNA) EPS (Weighted Average and Diluted) (2021 - 2024) Analysis & Trends
NuCana has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting $0.15 for Q2 2024.
- EPS (Weighted Average and Diluted) for Q2 2024 came in at $0.15, up 21.04% year-over-year; the trailing twelve-month figure through Jun 2023 was -$144.91 (down 583.81% YoY), and the FY2024 annual result was -$0.33, up 49.58% from the prior year.
- EPS (Weighted Average and Diluted) came in at $0.15 for Q2 2024 at NuCana, up from $0.13 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.15 in Q2 2024 to a low of -$29.64 in Q2 2021.
- The 4-year median for EPS (Weighted Average and Diluted) is -$10.53 (2022), against an average of -$12.64.
- Across the five-year window, EPS (Weighted Average and Diluted) soared 100.59% in 2023 and climbed 21.04% in 2024, its largest moves.
- NuCana's EPS (Weighted Average and Diluted) stood at -$29.64 in 2021, then grew by 28.51% to -$21.19 in 2022, then jumped by 100.59% to $0.13 in 2023, then gained by 21.04% to $0.15 in 2024.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.15 (Q2 2024), $0.13 (Q2 2023), and -$21.19 (Q2 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 0.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -0.61 |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 0.15 |
| Jun 30, 2023 | 0.13 |
| Jun 30, 2022 | -21.19 |
| Jun 30, 2021 | -29.64 |